Table 1.
Patient's characteristics and distribution PASC cohort and chronic fatigue cohort.
| PASC cohort (N = 134) | Chronic fatigue cohort (N = 105) persistent symptoms over 6 months | |||
|---|---|---|---|---|
| Characteristics | ME/CFS | No ME/CFS | Total— P -value | |
| Age (years) median (range) | 47 (20–88) | 50 (23–75) | 47 (21–88) | 47 (21–88), 0.26755835 |
| Sex: female/male (female %) | 79/55 (59%) | 26/19 (58%) | 42/18 (70%) | 68/38, 0.48175231 |
| Days post-COVID median (range) | 285.5 (34–792) | 318 (183–686) | 310 (149–792) | 310 (183–792), 0.13233956 |
| Diagnostic test N (%) | ||||
| Molecular/PCR | 119 (88.8%) | 38 (84%) | 54 (90%) | 92 |
| Antigen | 5 (3.7%) | 2 (6%) | 3 (5%) | 5 |
| Antibodies (+) before Vaccination | 10 (7.5%) | 5 (10%) | 3 (5%) | 8 |
| Treatment | ||||
| Ambulatory | 117/134 (87.3%) | 44 (98%) | 57 (95%) | 101 (96%) |
| Hospital | 17/134 (12.7%) | 1 (2%) | 3 (5%) | 4 (4%) |
| Functional status (%) | 0.0110474* | |||
| V (%) | 9 (6.8%) | 5 (11%) | 3 (5%) | 8 |
| IV (%) | 36 (27.1%) | 19 (42%) | 13 (22%) | 32 |
| III (%) | 64 (48.1%) | 20 (44%) | 27 (45%) | 47 |
| 1–II (%) | 20 (15%) | 1 (3%) | 17 (28%) | 18 |
| Co-morbid condition N (%) | 0.34714359 | |||
| None | 72 (53.7%) | 17 (38%) | 36 (60%) | 53 |
| One | 37 (27.6%) | 13 (29%) | 18 (30%) | 31 |
| Two | 15 (11.2%) | 7 (15%) | 5 (8%) | 12 |
| Three | 7 (5.2%) | 9 (18%) | 1 (2%) | 10 |
| BMI kg/m2 (median, range) | 0.00377895* | |||
| All | 26.2 (16.9–46.6) | 29.23 (18.9–47.9) | 25.6 (18.3–41.1) | 27.2 (16.9–46.6) |
| >30 (%) | 31 (33.6%) | 22 (49%) | 17 (28%) | 39 |
| >35 (%) | 21 (15%) | 10 (22%) | 8 (13%) | 19 |
| Race/ethnicity | ||||
| White | 66 (49.3%) | 17 (38%) | 34 (57%) | 51 |
| Hispanic | 23 (17.2%) | 13 (28%) | 7 (12%) | 20 |
| Black | 9 (6.7%) | 2 (4%) | 4 (7%) | 6 |
| Asian | 20 (14.9%) | 4 (8%) | 8 (13%) | 12 |
| Others | 2 (1.4%) | 1 (2%) | 1 (1%) | 2 |
| No data | 15 (11%) | 8 (18%) | 6 (10%) | 14 |
| Total | 134 (100%) | 45 (43%) | 60 (57%) | 105 (100%) |
PASC, Post-Acute Sequela of SARS-CoV-2 infection; ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
*
Statistical significant.